https://biotechmorning.com/news/odyssey-therapeutics-second-ipo-attempt Biotech Morning en 2026-04-20T14:07:40.639Z The $700M Biotech That Got Rejected by Wall Street Is Back for Round Two https://biotechmorning.com/news/astrazeneca-il33-tozorakimab-phase-3-copd-win Biotech Morning en 2026-04-20T14:07:04.833Z The Drug Target Everyone Gave Up On Just Won Again https://biotechmorning.com/news/novo-nordisk-sickle-cell-disease-etavopivat-phase-3 Biotech Morning en 2026-04-20T14:06:23.243Z Novo Nordisk's Quiet Bet on a Disease That Isn't Obesity https://biotechmorning.com/news/fda-rejects-replimune-melanoma-drug-twice-2 Biotech Morning en 2026-04-19T14:06:45.145Z The FDA Said No. Twice. Now Replimune Is Fighting for Survival. https://biotechmorning.com/news/foundayo-oral-obesity-pill-launch-prescriptions Biotech Morning en 2026-04-19T14:06:02.299Z The Obesity Pill That Just Changed the Game https://biotechmorning.com/news/fda-reclassifies-banned-peptides-compounding-pharmacies Biotech Morning en 2026-04-19T14:05:16.824Z The FDA Just Made 12 Banned Peptides Legal Again